JPH05507695A - 新規な治療 - Google Patents

新規な治療

Info

Publication number: JPH05507695A
Authority: JP; Japan
Prior art keywords: histamine; gastric; acid; use according; treatment
Prior art date: 1990-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP91510567A

Other languages

English (en)

Japanese (ja)

Inventor

デイビス，アドリアン　フランシス

Original Assignee

ビーチャム　グループ　ピーエルシー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-22

Filing date

1991-06-13

Publication date

1993-11-04

1990-06-22 Priority claimed from GB909013910A external-priority patent/GB9013910D0/en

1990-08-24 Priority claimed from GB909018676A external-priority patent/GB9018676D0/en

1991-06-13 Application filed by ビーチャム　グループ　ピーエルシー filed Critical ビーチャム　グループ　ピーエルシー

1993-11-04 Publication of JPH05507695A publication Critical patent/JPH05507695A/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims description 21
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 49
229940069428 antacid Drugs 0.000 claims description 32
239000003159 antacid agent Substances 0.000 claims description 32
239000005557 antagonist Substances 0.000 claims description 26
229960001340 histamine Drugs 0.000 claims description 24
239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 24
229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 23
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
230000001458 anti-acid effect Effects 0.000 claims description 14
230000002496 gastric effect Effects 0.000 claims description 14
208000018556 stomach disease Diseases 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
229960001380 cimetidine Drugs 0.000 claims description 10
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 10
230000003472 neutralizing effect Effects 0.000 claims description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
230000009858 acid secretion Effects 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
102000005962 receptors Human genes 0.000 claims description 6
108020003175 receptors Proteins 0.000 claims description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
208000025865 Ulcer Diseases 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 4
229960000620 ranitidine Drugs 0.000 claims description 4
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
239000000347 magnesium hydroxide Substances 0.000 claims description 3
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
239000000395 magnesium oxide Substances 0.000 claims description 3
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
230000014759 maintenance of location Effects 0.000 claims description 3
238000006386 neutralization reaction Methods 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
-1 alkali metal salts Chemical class 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
229940036348 bismuth carbonate Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
GMZOPRQQINFLPQ-UHFFFAOYSA-H dibismuth;tricarbonate Chemical compound [Bi+3].[Bi+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GMZOPRQQINFLPQ-UHFFFAOYSA-H 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
239000004334 sorbic acid Substances 0.000 claims description 2
235000010199 sorbic acid Nutrition 0.000 claims description 2
229940075582 sorbic acid Drugs 0.000 claims description 2
239000011975 tartaric acid Substances 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
208000012895 Gastric disease Diseases 0.000 claims 3
239000005711 Benzoic acid Substances 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
229910052782 aluminium Inorganic materials 0.000 claims 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
235000010210 aluminium Nutrition 0.000 claims 1
229940008027 aluminum hydroxide / magnesium carbonate Drugs 0.000 claims 1
235000010233 benzoic acid Nutrition 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
235000015165 citric acid Nutrition 0.000 claims 1
239000000499 gel Substances 0.000 claims 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
239000001095 magnesium carbonate Substances 0.000 claims 1
229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
239000000391 magnesium silicate Substances 0.000 claims 1
229910052919 magnesium silicate Inorganic materials 0.000 claims 1
235000019792 magnesium silicate Nutrition 0.000 claims 1
ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
235000011007 phosphoric acid Nutrition 0.000 claims 1
239000000203 mixture Substances 0.000 description 14
210000002784 stomach Anatomy 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
229940044551 receptor antagonist Drugs 0.000 description 6
239000002464 receptor antagonist Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
210000001519 tissue Anatomy 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
206010020601 Hyperchlorhydria Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
229960001596 famotidine Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000000938 histamine H1 antagonist Substances 0.000 description 2
210000001711 oxyntic cell Anatomy 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
208000030090 Acute Disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000028399 Critical Illness Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
101150056637 Hrh2 gene Proteins 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
LHPJBAIYHPWIOT-UHFFFAOYSA-K aluminum;magnesium;carbonate;hydroxide Chemical compound [OH-].[Mg+2].[Al+3].[O-]C([O-])=O LHPJBAIYHPWIOT-UHFFFAOYSA-K 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
206010020765 hypersomnia Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
RNDIHDKIZRODRW-UHFFFAOYSA-L magnesium;chloride;hydroxide Chemical compound [OH-].[Mg+2].[Cl-] RNDIHDKIZRODRW-UHFFFAOYSA-L 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
229960004872 nizatidine Drugs 0.000 description 1
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
239000010902 straw Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP91510567A 1990-06-22 1991-06-13 新規な治療 Pending JPH05507695A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB909013910A GB9013910D0 (en)	1990-06-22	1990-06-22	Novel treatment
GB9013910,6		1990-06-22
GB9018176,8		1990-08-24
GB909018676A GB9018676D0 (en)	1990-08-24	1990-08-24	Novel treatment
PCT/GB1991/000953 WO1992000102A1 (fr)	1990-06-22	1991-06-13	Nouveau traitement

Publications (1)

Publication Number	Publication Date
JPH05507695A true JPH05507695A (ja)	1993-11-04

Family

ID=26297238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP91510567A Pending JPH05507695A (ja)	1990-06-22	1991-06-13	新規な治療

Country Status (7)

Country	Link
EP (1)	EP0533770A1 (fr)
JP (1)	JPH05507695A (fr)
KR (1)	KR930701196A (fr)
AU (1)	AU7981391A (fr)
CA (1)	CA2085873A1 (fr)
IE (1)	IE912133A1 (fr)
WO (1)	WO1992000102A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2052698A1 (fr) *	1990-10-11	1992-04-12	Roger G. Berlin	Traitement des ulceres peptiques
CA2061520C (fr) *	1991-03-27	2003-04-22	Lawrence J. Daher	Systeme de delivrance accelerant l'effet et accroissant la puissance
GB9127150D0 (en) *	1991-12-20	1992-02-19	Smithkline Beecham Plc	Novel treatment
CA2110313C (fr) *	1992-12-01	2004-10-26	Edward John Roche	Compositions pharmaceutiques contenant un compose de guanidothiazole et antiacides
AU7255094A (en) *	1993-07-06	1995-02-06	Mcneil-Ppc, Inc.	H2 antagonist-antihistamine combinations
US5622980A (en) *	1993-08-17	1997-04-22	Applied Analytical Industries, Inc.	Oral compositions of H2-antagonists
ZA947553B (en) *	1993-09-30	1995-05-26	Glaxo Inc	Ranitidine and calcium carbonate pharmaceutical combination product
JP3587869B2 (ja) *	1993-12-16	2004-11-10	グラクソ・スミスクライン株式会社	医薬組成物
WO1996004888A1 (fr) *	1994-08-12	1996-02-22	Applied Analytical Industries, Inc.	Compositions d'antagonistes h2 s'administrant par voie orale
JP2001501224A (ja) *	1996-10-04	2001-01-30	メルクエンドカンパニーインコーポレーテッド	胸焼けを予防及び治療するための方法及び組成物
US5989588A (en) *	1996-10-04	1999-11-23	Merck & Co., Inc.	Methods and compositions for preventing and treating heartburn
EP1983827A4 (fr)	2006-02-01	2013-07-10	Stuart L Weg	Utilisation de compositions antifongiques pour traiter des conditions gastro-intestinales superieures
US10342841B2 (en)	2015-05-29	2019-07-09	Johnson & Johnson Consumer Inc.	Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids
US20160346342A1 (en)	2015-05-29	2016-12-01	Johnson & Johnson Consumer Inc.	Use of organic citrus extract with high antimicrobial capacity as a preservative system in liquids, emulsions, suspensions, creams and antacids
WO2017091166A1 (fr)	2015-11-26	2017-06-01	Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş.	Compositions pharmaceutiques stables et leur procédé de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3710462A1 (de)	1987-03-30	1988-10-13	Heumann Pharma Gmbh & Co	Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
EP0294933B1 (fr)	1987-05-08	1992-03-11	Smith Kline & French Laboratories Limited	Compositions pharmaceutiques

1991
- 1991-06-13 JP JP91510567A patent/JPH05507695A/ja active Pending
- 1991-06-13 KR KR1019920703296A patent/KR930701196A/ko not_active Withdrawn
- 1991-06-13 AU AU79813/91A patent/AU7981391A/en not_active Abandoned
- 1991-06-13 CA CA002085873A patent/CA2085873A1/fr not_active Abandoned
- 1991-06-13 WO PCT/GB1991/000953 patent/WO1992000102A1/fr not_active Ceased
- 1991-06-13 EP EP91911107A patent/EP0533770A1/fr not_active Withdrawn
- 1991-06-20 IE IE213391A patent/IE912133A1/en unknown

Also Published As

Publication number	Publication date
WO1992000102A1 (fr)	1992-01-09
AU7981391A (en)	1992-01-23
EP0533770A1 (fr)	1993-03-31
KR930701196A (ko)	1993-06-11
IE912133A1 (en)	1992-01-01
CA2085873A1 (fr)	1991-12-23

Publication	Publication Date	Title
US5656652A (en)	1997-08-12	Compositions containing histamine-H2 -receptor antagonists at low dosage
US5244670A (en)	1993-09-14	Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
JPH05507695A (ja)	1993-11-04	新規な治療
EP0428296B1 (fr)	1994-06-08	Compositions pharmaceutiques pour le traitement de problèmes gastro-intestinaux
GB2222772A (en)	1990-03-21	Pharmaceutical compositions containing ranitidine
RU2126249C1 (ru)	1999-02-20	Фармацевтическая композиция для перорального введения для лечения патологического состояния верхних отделов желудочно-кишечного тракта
US4252790A (en)	1981-02-24	Method for treating gastric ulcer-prone patients
ITMI20070517A1 (it)	2008-02-11	Composizione solida farmaceutica contenente una associazione di un agente regolatore della motilita' intestinale ed un antiflatulente.
US4537771A (en)	1985-08-27	Antacids containing zeolitic molecular sieves
AU659422B2 (en)	1995-05-18	Composition containing antihistamine H2 receptor antagonists and bioadhesive material
AU2006270162B2 (en)	2012-01-12	A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
JPH0539219A (ja)	1993-02-19	胸やけ、胃痛または胃酸過多に関連した胃の不調の発泡性ｈ２ブロツカー製剤による治療
JP7669493B2 (ja)	2025-04-28	酸化マグネシウムを含有する小児慢性機能性便秘症治療用医薬組成物
JP6490742B2 (ja)	2019-03-27	内服用組成物
EP1992345A1 (fr)	2008-11-19	Combinaison synergique d'inhibiteurs des récepteurs h2, de silicone inerte et d'un complexe d'aluminate d'hydroxymagnésium
WO1996002262A2 (fr)	1996-02-01	Compositions pharmaceutiques pour le traitement de douleurs gastriques, comprenant des antiacides et des antagonistes des recepteurs h2 a l'histamine
JP6385642B2 (ja)	2018-09-05	内服用組成物
WO1998024455A1 (fr)	1998-06-11	Compositions pharmaceutiques ingerables pour le traitement des troubles du tractus gastro-intestinal superieur
CN1140996A (zh)	1997-01-22	雷尼替丁和碳酸钙药物复合品
JP2002205939A (ja)	2002-07-23	抗潰瘍剤組成物
JPH0840917A (ja)	1996-02-13	向上した安全性側面を有する制酸薬調剤